161 related articles for article (PubMed ID: 35169036)
1. Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study.
Furie RA; Hough DR; Gaudy A; Ye Y; Korish S; Delev N; Weiswasser M; Zhan X; Schafer PH; Werth VP
Lupus Sci Med; 2022 Feb; 9(1):. PubMed ID: 35169036
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.
Merrill JT; Werth VP; Furie R; van Vollenhoven R; Dörner T; Petronijevic M; Velasco J; Majdan M; Irazoque-Palazuelos F; Weiswasser M; Korish S; Ye Y; Gaudy A; Schafer PH; Liu Z; Agafonova N; Delev N
N Engl J Med; 2022 Mar; 386(11):1034-1045. PubMed ID: 35294813
[TBL] [Abstract][Full Text] [Related]
3. Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus.
Schafer PH; Ye Y; Wu L; Kosek J; Ringheim G; Yang Z; Liu L; Thomas M; Palmisano M; Chopra R
Ann Rheum Dis; 2018 Oct; 77(10):1516-1523. PubMed ID: 29945920
[TBL] [Abstract][Full Text] [Related]
4. Biological impact of iberdomide in patients with active systemic lupus erythematosus.
Lipsky PE; Vollenhoven RV; Dörner T; Werth VP; Merrill JT; Furie R; Petronijevic M; Velasco Zamora B; Majdan M; Irazoque-Palazuelos F; Terbrueggen R; Delev N; Weiswasser M; Korish S; Stern M; Hersey S; Ye Y; Gaudy A; Liu Z; Gagnon R; Tang S; Schafer PH
Ann Rheum Dis; 2022 Apr; 81(8):1136-42. PubMed ID: 35477518
[TBL] [Abstract][Full Text] [Related]
5. First-in-Human, Single- and Multiple-Ascending-Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator.
Ye Y; Gaudy A; Schafer P; Thomas M; Weiss D; Chen N; Liu L; Xue Y; Carayannopoulos L; Palmisano M
Clin Pharmacol Drug Dev; 2021 May; 10(5):471-485. PubMed ID: 32969202
[TBL] [Abstract][Full Text] [Related]
6. A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis.
Cohen S; Beebe JS; Chindalore V; Guan S; Hassan-Zahraee M; Saxena M; Xi L; Hyde C; Koride S; Levin R; Lubaczewski S; Salganik M; Sloan A; Stevens E; Peeva E; Vincent MS; Martin DA; Chu M
Arthritis Res Ther; 2024 Jun; 26(1):117. PubMed ID: 38845046
[TBL] [Abstract][Full Text] [Related]
7. Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease.
McDonnell SRP; Nguyen VA; Walton NM; Merkwirth C; Hong F; Berg D; Muensterman ET; Furie RA
Lupus Sci Med; 2024 Mar; 11(1):. PubMed ID: 38453421
[TBL] [Abstract][Full Text] [Related]
8. Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus.
Rivellese F; Manou-Stathopoulou S; Mauro D; Goldmann K; Pyne D; Rajakariar R; Gordon P; Schafer P; Bombardieri M; Pitzalis C; Lewis MJ
Lupus Sci Med; 2021 Mar; 8(1):. PubMed ID: 33727237
[TBL] [Abstract][Full Text] [Related]
9. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus.
Furie RA; Bruce IN; Dörner T; Leon MG; Leszczyński P; Urowitz M; Haier B; Jimenez T; Brittain C; Liu J; Barbey C; Stach C
Rheumatology (Oxford); 2021 Nov; 60(11):5397-5407. PubMed ID: 33956056
[TBL] [Abstract][Full Text] [Related]
10. [Iberdomide against Aiolos and Ikaros in systemic lupus erythematosus].
Mucke J
Z Rheumatol; 2022 Sep; 81(7):608-609. PubMed ID: 35704067
[No Abstract] [Full Text] [Related]
11. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.
Szepietowski JC; Nilganuwong S; Wozniacka A; Kuhn A; Nyberg F; van Vollenhoven RF; Bengtsson AA; Reich A; de Vries DE; van Hartingsveldt B; Robinson DW; Gordon R; Hsu B
Arthritis Rheum; 2013 Oct; 65(10):2661-71. PubMed ID: 23896980
[TBL] [Abstract][Full Text] [Related]
12. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
Wallace DJ; Stohl W; Furie RA; Lisse JR; McKay JD; Merrill JT; Petri MA; Ginzler EM; Chatham WW; McCune WJ; Fernandez V; Chevrier MR; Zhong ZJ; Freimuth WW
Arthritis Rheum; 2009 Sep; 61(9):1168-78. PubMed ID: 19714604
[TBL] [Abstract][Full Text] [Related]
13. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.
Khamashta M; Merrill JT; Werth VP; Furie R; Kalunian K; Illei GG; Drappa J; Wang L; Greth W;
Ann Rheum Dis; 2016 Nov; 75(11):1909-1916. PubMed ID: 27009916
[TBL] [Abstract][Full Text] [Related]
14. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.
Petri M; Wallace DJ; Spindler A; Chindalore V; Kalunian K; Mysler E; Neuwelt CM; Robbie G; White WI; Higgs BW; Yao Y; Wang L; Ethgen D; Greth W
Arthritis Rheum; 2013 Apr; 65(4):1011-21. PubMed ID: 23400715
[TBL] [Abstract][Full Text] [Related]
15. Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles.
Chamberlain C; Colman PJ; Ranger AM; Burkly LC; Johnston GI; Otoul C; Stach C; Zamacona M; Dörner T; Urowitz M; Hiepe F
Ann Rheum Dis; 2017 Nov; 76(11):1837-1844. PubMed ID: 28780512
[TBL] [Abstract][Full Text] [Related]
16. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
Merrill JT; Wallace DJ; Petri M; Kirou KA; Yao Y; White WI; Robbie G; Levin R; Berney SM; Chindalore V; Olsen N; Richman L; Le C; Jallal B; White B;
Ann Rheum Dis; 2011 Nov; 70(11):1905-13. PubMed ID: 21798883
[TBL] [Abstract][Full Text] [Related]
17. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
Morand E; Pike M; Merrill JT; van Vollenhoven R; Werth VP; Hobar C; Delev N; Shah V; Sharkey B; Wegman T; Catlett I; Banerjee S; Singhal S
Arthritis Rheumatol; 2023 Feb; 75(2):242-252. PubMed ID: 36369798
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study.
van Vollenhoven RF; Hahn BH; Tsokos GC; Lipsky P; Gordon RM; Fei K; Lo KH; Chevrier M; Rose S; Berry P; Yao Z; Karyekar CS; Zuraw Q
J Rheumatol; 2022 Apr; 49(4):380-387. PubMed ID: 34853089
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
van Vollenhoven RF; Hahn BH; Tsokos GC; Wagner CL; Lipsky P; Touma Z; Werth VP; Gordon RM; Zhou B; Hsu B; Chevrier M; Triebel M; Jordan JL; Rose S
Lancet; 2018 Oct; 392(10155):1330-1339. PubMed ID: 30249507
[TBL] [Abstract][Full Text] [Related]
20. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
